The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases. Issue 3 (March 2020)
- Record Type:
- Journal Article
- Title:
- The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases. Issue 3 (March 2020)
- Main Title:
- The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases
- Authors:
- Asoglu, Oktar
Tokmak, Handan
Bakir, Baris
Demir, Gokhan
Ozyar, Enis
Atalar, Banu
Goksel, Suha
Koza, Burak
Guven Mert, Aslihan
Demir, Atakan
Guven, Koray - Abstract:
- Abstract: Background: The study aimed to assess if adherence to a total-neoadjuvant-treatment (TNT) protocol followed by observation(watch-and-wait) led to the successful nonoperative-management of low-rectal-cancer. Methods: In this study, patients with primary, resectable-T3-T4, N0–N1 distal-rectal-adenocarcinoma underwent-chemoradiotherapy + consolidation-chemotherapy (TNT). During the-TNT-period, endoscopy, MRI, and FDG-PET/CT were performed. We allocated patients with complete-clinical-tumor-regression, who underwent endoscopy every two months, MRI every-four-months, and PET/CT every-six-months-after-treatment, to the observation-group(OG). All other patients were referred for surgery. The OG was followed-up. The primary endpoint was local tumor-ecurrence after allocation to the OG. Results: Between 2015 and 2018, we enrolled 66-patients. Of 60-patients who were eligible to participate, 39 had complete-clinical-response(cCR) and were allocated to the OG, six underwent local-excision (LE), and 15 underwent total-mesorectal-excision (TME). The median follow-up duration was 22 (9–42) months. The local-recurrence-rate in the OG was 15.3%, and the LE and TME rates were 16.6% and 0%, respectively. All recurrence cases were salvaged through either LE or TME. The-distant-metastasis rate was 5.1%, 16.6%, and 12.5% in the OG, LE, and TME groups, respectively. The endoscopic negative-predictive-value(NPV) was 50%, and the positive-predictive-value(PPV) was 76.9% in the surgeryAbstract: Background: The study aimed to assess if adherence to a total-neoadjuvant-treatment (TNT) protocol followed by observation(watch-and-wait) led to the successful nonoperative-management of low-rectal-cancer. Methods: In this study, patients with primary, resectable-T3-T4, N0–N1 distal-rectal-adenocarcinoma underwent-chemoradiotherapy + consolidation-chemotherapy (TNT). During the-TNT-period, endoscopy, MRI, and FDG-PET/CT were performed. We allocated patients with complete-clinical-tumor-regression, who underwent endoscopy every two months, MRI every-four-months, and PET/CT every-six-months-after-treatment, to the observation-group(OG). All other patients were referred for surgery. The OG was followed-up. The primary endpoint was local tumor-ecurrence after allocation to the OG. Results: Between 2015 and 2018, we enrolled 66-patients. Of 60-patients who were eligible to participate, 39 had complete-clinical-response(cCR) and were allocated to the OG, six underwent local-excision (LE), and 15 underwent total-mesorectal-excision (TME). The median follow-up duration was 22 (9–42) months. The local-recurrence-rate in the OG was 15.3%, and the LE and TME rates were 16.6% and 0%, respectively. All recurrence cases were salvaged through either LE or TME. The-distant-metastasis rate was 5.1%, 16.6%, and 12.5% in the OG, LE, and TME groups, respectively. The endoscopic negative-predictive-value(NPV) was 50%, and the positive-predictive-value(PPV) was 76.9% in the surgery group (LE + TME). MRI; NPV-50%, PPV-76.9%. PET/CT; NPV-100%, PPV-93.3%. Six patients(28.57%) from surgery group achieved complete pathological response (cPR). Conclusion: Our results indicated a high proportion of selected-rectal-cancers with-cCR after neo-adjuvant-therapy could potentially be managed non-operatively, and major surgery may be avoided. … (more)
- Is Part Of:
- European journal of surgical oncology. Volume 46:Issue 3(2020)
- Journal:
- European journal of surgical oncology
- Issue:
- Volume 46:Issue 3(2020)
- Issue Display:
- Volume 46, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 46
- Issue:
- 3
- Issue Sort Value:
- 2020-0046-0003-0000
- Page Start:
- 402
- Page End:
- 409
- Publication Date:
- 2020-03
- Subjects:
- Watch and wait -- Non operative management -- PET/CT -- pCR -- cCR -- TRG
Oncology -- Periodicals
Cancer -- Surgery -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- surgery -- Periodicals
Cancer -- Chirurgie -- Périodiques
Cancérologie -- Périodiques
Oncologie
Chirurgie (geneeskunde)
Electronic journals
Electronic journals -- Sciences
Electronic journals -- Medicine
Electronic journals
616.994059005 - Journal URLs:
- http://www.ejso.com/ ↗
http://www.sciencedirect.com/science/journal/07487983 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/07487983 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0720048X ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0748-7983;screen=info;ECOIP ↗
http://www.elsevier.com/journals ↗
http://www.harcourt-international.com/journals ↗
http://www.idealibrary.com/cgi-bin/links/toc/ejso ↗ - DOI:
- 10.1016/j.ejso.2019.07.012 ↗
- Languages:
- English
- ISSNs:
- 0748-7983
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.745500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23165.xml